USA - NASDAQ:NUWE - US67113Y7022 - Common Stock
The current stock price of NUWE is 2.71 USD. In the past month the price decreased by -20.76%. In the past year, price decreased by -96.42%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 25.23 | 219.11B | ||
| ISRG | INTUITIVE SURGICAL INC | 66.92 | 206.56B | ||
| BSX | BOSTON SCIENTIFIC CORP | 34.21 | 149.52B | ||
| SYK | STRYKER CORP | 26.96 | 135.73B | ||
| IDXX | IDEXX LABORATORIES INC | 56.27 | 56.77B | ||
| BDX | BECTON DICKINSON AND CO | 12.6 | 52.06B | ||
| EW | EDWARDS LIFESCIENCES CORP | 32.72 | 49.36B | ||
| RMD | RESMED INC | 25.26 | 36.50B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 16.01 | 33.55B | ||
| PODD | INSULET CORP | 70.1 | 22.55B | ||
| DXCM | DEXCOM INC | 29.48 | 21.51B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 10.97 | 17.58B |
Nuwellis, Inc. operates as a medical device company. The company is headquartered in Eden Prairie, Minnesota and currently employs 38 full-time employees. The company went IPO on 2012-02-16. The firm is focused on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy, including the Aquadex FlexFlow and the Aquadex SmartFlow systems (collectively the Aquadex System). The Aquadex SmartFlow system is indicated for temporary or extended use in adult and pediatric patients weighing 20 kilograms or more whose fluid overload is unresponsive to medical management, including diuretics. The Aquadex System is designed to remove excess fluid from patients suffering from fluid overload who have failed diuretic therapy. The Aquadex System consists of a console, which is a piece of equipment containing electromechanical pumps and a liquid crystal display (LCD) screen; a one-time disposable blood circuit set, which is an integrated collection of tubing, filters, sensors, and connectors that contain and deliver the blood from and back to the patient, and a disposable catheter.
NUWELLIS INC
12988 Valley View Rd
Eden Prairie MINNESOTA 55344 US
CEO: Nestor Jaramillo
Employees: 38
Phone: 19523454200
Nuwellis, Inc. operates as a medical device company. The company is headquartered in Eden Prairie, Minnesota and currently employs 38 full-time employees. The company went IPO on 2012-02-16. The firm is focused on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy, including the Aquadex FlexFlow and the Aquadex SmartFlow systems (collectively the Aquadex System). The Aquadex SmartFlow system is indicated for temporary or extended use in adult and pediatric patients weighing 20 kilograms or more whose fluid overload is unresponsive to medical management, including diuretics. The Aquadex System is designed to remove excess fluid from patients suffering from fluid overload who have failed diuretic therapy. The Aquadex System consists of a console, which is a piece of equipment containing electromechanical pumps and a liquid crystal display (LCD) screen; a one-time disposable blood circuit set, which is an integrated collection of tubing, filters, sensors, and connectors that contain and deliver the blood from and back to the patient, and a disposable catheter.
The current stock price of NUWE is 2.71 USD. The price decreased by -5.57% in the last trading session.
NUWE does not pay a dividend.
NUWE has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
NUWE stock is listed on the Nasdaq exchange.
NUWELLIS INC (NUWE) currently has 38 employees.
NUWELLIS INC (NUWE) will report earnings on 2025-11-10, before the market open.
ChartMill assigns a fundamental rating of 2 / 10 to NUWE. NUWE may be in some trouble as it scores bad on both profitability and health.
Over the last trailing twelve months NUWE reported a non-GAAP Earnings per Share(EPS) of -769.02. The EPS decreased by -71.92% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -159.51% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
For the next year, analysts expect an EPS growth of 99.74% and a revenue growth 2.8% for NUWE